In Brief
Dengue-specific antibodies can crossreact to Zika virus. Brown et al. demonstrate that dengue-specific antibodies can enhance Zika virus pathogenesis during pregnancy by increasing damage to the placenta. These findings suggest a possible mechanism for the recent increase in severe pregnancy outcomes after Zika virus infection in areas where dengue cocirculates.
INTRODUCTION
Zika virus (ZIKV) is a mosquito-transmitted flavivirus that is closely related to dengue virus (DENV). In the 60 years after its discovery in 1947, ZIKV remained a relatively obscure pathogen, associated with only sporadic cases of human infection and mild febrile illness (Weaver et al., 2016) . In the last decade, however, after its geographic spread into the Pacific Islands and then South America, ZIKV outbreaks have been larger, more frequent, and more severe (Lazear and Diamond, 2016) . Most concerning are infections in pregnant women, particularly during the first and second trimesters, which have resulted in a wide range of birth defects, including microcephaly, intrauterine growth restriction, and spontaneous abortion (Brasil et al., 2016; Coyne and Lazear, 2016; Honein et al., 2017; Reynolds et al., 2017; Schaub et al., 2017) . The factors involved in this increased pathogenesis of ZIKV are not fully understood but may include recently acquired viral genetic changes (Yuan et al., 2017) , as well as prior exposure to closely related flaviviruses (Bardina et al., 2017) . The latter is due to a phenomenon originally described between DENV serotypes, known as antibody-dependent enhancement (ADE). In humans, ADE between DENV serotypes has been shown to correlate with increased viremia and disease severity within a specific window of waning heterotypic antibody levels (Halstead, 1988; Katzelnick et al., 2017; Kliks et al., 1988; Vaughn et al., 2000) ; however, the extent to which antibodies against DENV and potentially other flaviviruses can cause enhanced ZIKV pathogenesis in humans has not been thoroughly evaluated.
Studies have shown that the ZIKV envelope (E) protein has high structural similarity to the E proteins of all DENV serotypes Kostyuchenko et al., 2016; Sirohi et al., 2016) . Numerous in vitro studies have demonstrated that monoclonal antibodies or sera elicited by infection with DENV can enhance ZIKV replication (Bardina et al., 2017; Dejnirattisai et al., 2016; Paul et al., 2016; Priyamvada et al., 2016; Stettler et al., 2016; Willis and Hensley, 2017) . Recently, our group demonstrated that pre-existing antibodies to DENV increased ZIKV pathogenesis in adult Stat2 À/À mice (Bardina et al., 2017 ).
This raises a major question about whether DENV antibodies impart a heightened risk on the developing fetus after maternal ZIKV infection. Here, we examined this question with both an in vivo model of ZIKV ADE in pregnant Stat2 À/À mice and an ex vivo model with human placental tissues. We show that the presence of DENV antibodies in mice increased damage to the placenta and worsened pregnancy outcomes in an FcgR-dependent manner. In both mouse and human placentas, the presence of DENV antibodies enhanced replication of ZIKV, which was associated with an increased frequency of infected trophoblasts. Our data suggest a possible mechanism for the enhancement of ZIKV pathogenesis in the placenta, indirectly enhancing fetal damage.
nearly identical phenotype, with increased maternal weight loss, higher fetal resorption rates, and decreased fetal size, was observed with the purified DENV IgG compared to the unfractionated DENV-immune plasma. Maternal health monitoring throughout the course of the 7-day infection revealed only minor symptoms among the infected pregnant mice, with hesitancy to walk being the only indication of infection. This symptom was observed more frequently among mice receiving DENV antibodies compared to mice receiving CTRL antibodies ( Figure 1I ). Interestingly, we also observed vaginal bleeding in 22.2% of mice receiving DENV antibodies, but not in mice receiving CTRL antibodies, consistent with the increased rate of fetal resorption observed in the DENV condition. Analysis of peripheral blood obtained on day 3 post infection from ZIKV-infected dams at E9.5 showed higher viremia in mice receiving DENV antibodies ( Figure 1J ; p = 0.003), but no differences in tissue viral loads in the brain or spinal cord were observed in the pregnant dams , which notably differed from our previous report in non-pregnant Stat2 À/À mice. This difference is most likely due to the increased age of the Stat2 À/À mice (8-10 weeks old) used in this study compared to those used in our previous study ($5-6 weeks old) and immune alterations due to pregnancy such as hormonal changes, increased weight gain, and blood volume (Kourtis et al., 2014) . Our data suggest that DENV antibodies can enhance ZIKV pathogenesis in the context of pregnancy, leading to increased fetal damage.
Dengue Virus Antibodies Increase ZIKV Replication and Inflammation in the Placenta
To further characterize how DENV-specific antibodies alter pregnancy outcomes, we next measured viral replication in both the fetus and the placenta. As shown in Figure 2A , mice receiving DENV-immune plasma showed significantly higher ZIKV replication in the placenta ($6-fold increase) compared to CTRLtreated animals (p < 0.0001), whereas the fetal head showed no differences between the groups ( Figure 2B ; p = 0.8423).
The increased viral load observed within placentas obtained from DENV-antibody-treated mice coincided with a stronger proinflammatory response in those placentas ( Figure 2C ). Histopathological analysis of placentas obtained at E13.5 from ZIKVinfected pregnant dams treated with DENV antibodies revealed more severe damage caused by infection compared to placentas of CTRL-treated animals, with a smaller, less-defined labyrinth zone ( Figure 2D , black outline) and a more pronounced loss of structural integrity visible through immunofluorescence staining for vimentin, a marker for endothelium in fetal capillaries ( Figure 2E ). Collectively, these results suggest that rather than directly enhancing ZIKV replication within the fetal brain, DENV antibodies exacerbate damage to the fetus by enhancing ZIKV replication and inflammation in the placenta.
Dengue Virus Antibodies Enhance ZIKV Pathogenesis at Advanced Gestational Age In mice infected with ZIKV on E6.5, peak viremia occurs 3 days post infection at E9.5, which coincides with the initial formation of the placenta ($E9-E10). This raises the question of whether cross-reactive DENV-specific antibodies could also impact ZIKV infection later in gestation, after full placentation has occurred. This is particularly interesting because recent studies have shown that ZIKV-induced fetal damage in both mice and non-human primates is highly dependent on gestational age, with susceptibility decreasing as gestation progresses (Dudley et al., 2018; Jagger et al., 2017) . To this end, we infected Stat2
pregnant dams at E10.5 in the presence of DENV or CTRL immune plasma. Consistent with previously published results (Jagger et al., 2017) , mice infected at this advanced gestational age showed more resistance to ZIKV, with weight gain, resorption rates, and fetal sizes among the ZIKV-infected group receiving CTRL antibodies nearly identical to that of uninfected mice ( Figures 3A-3D ). Fetal resorption rates in dams infected in the presence of DENV antibodies also remained unaltered. However, the presence of DENV-specific antibodies notably increased maternal weight loss (p = 0.04) and resulted in smaller fetuses at E16.5 (p = 0.001; Figures 3A-3D ). Maternal Figure 1 . In Vivo Effects of Preexisting DENV Antibodies on ZIKV Pathogenesis during Pregnancy (A-H) Pregnant dams at E6.5 were infected intradermally with 5310 3 PFU (plaque-forming unit) ZIKV PRVABC59 2 h after passive transfer of 20 ml CTRL or DENV immune plasma (A-D) or 2 ml purified IgG (E-H). Daily weight measurements after ZIKV infection (A and E) are shown as the percentage of maternal starting weight for uninfected mice (A, n = 8; E, n = 3) as well as ZIKV-infected mice in the presence of CTRL (A, n = 6; E, n = 4) or DENV (A, n = 8; E, n = 3) immune plasma/IgG. Uninfected mice were also injected with immune plasma or IgG and found to be identical for all parameters tested ( Figure S1 ) and were thus combined for the corresponding analyses. Mean ± SEM. (B and F) Resorption rates at E13.5 of uninfected pregnant dams (B, n = 59; F, n = 25) or ZIKV-infected pregnant dams in the presence of CTRL (B, n = 46; F, n = 29) or DENV immune plasma/IgG (B, n = 42; F, n = 23) were measured. (C and G) Representative images of uterine horns, fetuses and placentas at E13.5 are shown. (D and H) Fetal size was assessed at E13.5 by multiplying the crown-to-rump length (CRL) by the occipital-frontal diameter (OFD). Each data point represents an individual fetus. Median ± interquartile range.
(I) Mice were monitored daily for clinical symptoms, including hesitancy to walk, unresponsiveness, and limb paralysis; vaginal bleeding was also observed in a subset of pregnant mice.
(J-L) Viral load was quantified by qPCR from maternal blood three days post infection at E9.5 (J) as well as from the maternal brains (K) and spinal cords (L) on day 7 post infection at E13.5. Median ± interquartile range. For (A), (D), (E), and (H), significance was determined by one-way ANOVA corrected using Bonferroni's test for multiple comparisons; Fisher's exact test was used to calculate significance in (B) and (F). For (J)-(L), significance was determined by the Mann-Whitney test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figures S1 and S2.
health monitoring revealed no symptom development or vaginal bleeding in any experimental group (data not shown), consistent with the unaltered resorption rates. Likewise, no significant differences in maternal viral loads were observed ( Figures  3E-3G ). We observed approximately a 5-fold increase in viral load in the placentas of mice receiving DENV antibodies compared to mice receiving CTRL antibodies (p = 0.0001; Figure 3H ), but no difference in viral load in the fetal head was observed between the DENV and CTRL groups (p = 0.3134; Figure 3I) , similar to our results from mice infected at E6.5. This increased viral load in the placentas was associated with increased placental damage, marked by a reduced labyrinth zone ( Figure 3J , black outline) and greater breakdown of the endothelial network ( Figure 3K ). Together, our data suggest that although mice are more resistant to fetal damage with increased gestational age, the presence of DENV antibodies still exacerbates ZIKV-mediated damage to the fetus that correlates with increased viral replication and damage to the placenta.
Cellular Tropism of ZIKV Is Expanded in the Placenta in the Presence of DENV Antibodies Evidence of placental pathology has been shown in mice, nonhuman primates, and humans after ZIKV infection, suggesting that placental damage may play a key role in ZIKV-mediated damage to the developing fetus (Dudley et al., 2018; Hirsch et al., 2018; Jagger et al., 2017; Martines et al., 2016; Martinot et al., 2018; Miner et al., 2016; Mlakar et al., 2016; Nguyen et al., 2017; Noronha et al., 2016; Seferovic et al., 2018; Yockey et al., 2018) . Several previous studies, in both mice and humans, have identified macrophages (Hofbauer cells) and trophoblasts as potential in vivo targets for ZIKV within the placenta (Aagaard et al., 2017; El Costa et al., 2016; Miner et al., 2016; Quicke et al., 2016; Sheridan et al., 2017; Zimmerman et al., 2018) . Given the increased viral load within the placenta in the presence of DENV-specific antibodies (Figure 2A ), we sought to determine whether antibody-mediated entry of ZIKV altered the nature of the infected cell population within the placenta. To evaluate ZIKV infection among macrophages and trophoblasts, we conducted in situ hybridization for ZIKV RNA in conjunction with immunofluorescence staining for the macrophage marker MAC-2 or the trophoblast marker cytokeratin 19 (CK19) to identify infected cells. In placentas from mice receiving CTRL antibodies, cells positive for ZIKV RNA were found largely at the placenta-decidua interface, whereas in the presence of DENV antibodies, ZIKV-infected cells could be found infiltrated throughout the placenta ( Figures 4A and S3A ). Although we observed a greater number of ZIKV-infected macrophages in the placentas of mice receiving DENV antibodies, the overall proportion of ZIKV-infected macrophages was not significantly altered (5.0% for DENV condition versus 2.6% for CTRL condition; p = 0.8976; Figure 4B ). When evaluating ZIKV infection among trophoblasts, we observed essentially no co-staining in the placentas from mice that received CTRL antibodies. However, in the placentas from mice receiving DENV antibodies, we observed a striking increase in the proportion of ZIKV-infected trophoblasts (10.8% for DENV condition versus 0.13% for CTRL condition; p = 0.0028; Figures 4C, 4D , and S3B). These data show that the presence of DENV antibodies greatly increases the infection of trophoblasts, which may contribute to increased viral replication and structural damage to the placenta. 
DENV Antibodies Increase ZIKV Replication in Human Placentas Ex Vivo
To determine whether our observations in the murine placenta may be relevant for human ZIKV infections, we adopted an ex vivo model of ZIKV infection using human placental tissues as previously described (Corry et al., 2017; Platt et al., 2018; Weisblum et al., 2017) . We compared ZIKV replication in the presence of either DENV-or CTRL immune plasma using first and second trimester placentas from healthy human donors. Fetal-derived chorionic villi were isolated, cut, and placed in (E-I) Maternal blood (E) was collected 3 days post infection at E13.5, and maternal spinal cords (F), maternal brains (G), placentas (H), and fetal heads (I) were collected at day 6 post infection (E16.5) for viral RNA quantification by qPCR. Median ± interquartile range.
(J and K) H&E staining (J) and immunofluorescence staining of vimentin (K) were conducted on placentas harvested on day 6 post infection. For (J), the black line denotes the labyrinth zone and the gray line denotes the boundary between the decidua and the giant trophoblast layer. For (K), blue = DAPI, green = vimentin. Scale bars indicate 500 mm. For (A) and (D), significance was determined by one-way ANOVA corrected using Bonferroni's test for multiple comparisons; Fisher's exact test was used to calculate significance in (B). For (E)-(I), significance was determined by the Mann-Whitney test. *p < 0.05, **p < 0.01, ***p < 0.001.
tissue culture overnight ( Figure S4A ). Tissues were then infected with ZIKV that had been pre-incubated with CTRL or DENV immune plasma. Culture supernatants were sampled throughout the 6-day culture, during which time production of human placental lactogen and chorionic gonadotropin remained robust, demonstrating that placental tissue remained functional (Figures S4B and S4C) . At the earliest time point (day 2 post infection), all 11 donor placentas showed an increase in viral replication in the presence of DENV-immune plasma that ranged between 3-to 1,000-fold above ZIKV titers in the presence of CTRL immune plasma (p = 0.001; Figure 5A ). This increase continued throughout the course of the infection for all donor placentas on day 4 (p = 0.001; Figure 5B ) and was maintained in 10 of the 11 donor placentas through day 6 (p = 0.018; Figure 5C ). We repeated these experiments using purified IgG, which showed a similar increase in viral replication in the presence of DENV IgG in all donors tested ( Figures 5D-5F ). To determine the dependence of this activity on Fcg receptor (FcgR) engagement as well as on neonatal Fc receptor (FcRn) engagement, we pre-incubated the placental tissues with blocking antibodies against FcgRI (anti-CD64), FcgRII (anti-CD32), FcgRIII (anti-CD16), or anti-FcRn prior to infection. All blocking antibodies were able to decrease ZIKV replication in human placentas (A-D) Placenta sections from ZIKV-infected mice receiving either CTRL or DENV immune plasma or placentas from uninfected pregnant dams were co-stained for ZIKV RNA by in situ hybridization (red) with either macrophage marker (MAC-2; A) or trophoblast marker CK19 (C) in green; nuclei were stained with DAPI (blue). Scale bars indicate 500 mm for the top panels and 100 mm for the remaining panels. Cells double positive for ZIKV RNA and either MAC-2 (B) or CK19 (D) were quantified. Nine placentas were imaged in the DENV condition and five placentas were imaged in the CTRL condition. The Mann-Whitney test was used to determine significance. **p < 0.01 See also Figure S3 .
( Figures 5G-5J ). Our data show that DENV antibodies can enhance ZIKV replication in human placentas in a manner that is Fc-receptor dependent.
Dengue Virus-Specific Antibodies Promote ZIKV Infection of Trophoblasts in Human Placentas
To further tease apart the mechanism of ZIKV ADE in human placentas, we evaluated the ZIKV-infected cells using both in situ hybridization for ZIKV RNA and ZIKV NS3 antibody staining combined with immunofluorescence staining for macrophages and trophoblasts. Evaluation of co-stained cells revealed that the overall proportion of macrophages infected with ZIKV remained unchanged in the presence or absence of DENV antibodies (3.64% in the CTRL condition versus 3.65% in the DENV condition; p = 0.9375; Figures 6A, 6B, and S5A), consistent with our observations in mice. Furthermore, co-staining for ZIKV and CK19 revealed an approximately 10-fold increase in the proportion of placental trophoblasts infected with ZIKV, with 1.2% of trophoblasts co-staining with ZIKV in the absence of enhancing antibodies (CTRL-treated) and 12.4% in the presence of DENV antibodies (p = 0.0156; Figures 6C, 6D , and S5B), again consistent with our observations in placentas from ZIKV-infected Stat2 À/À mice. To distinguish between syncytiotrophoblasts and cytotrophoblasts, we co-stained placental tissue for ZIKV RNA and syncytin, a marker for syncytiotrophoblasts in the placenta. We observed a trend of increased ZIKV-infected syncytiotrophoblasts in the presence of DENV antibodies in all three donors tested, but this increase was not as striking as the overall increase in CK19-stained trophoblasts, with 1.9% of syncytiotrophoblasts infected in the presence of CTRL antibodies and 6.5% infected in the presence of DENVspecific antibodies (p = 0.25; Figures S6A and S6B) , suggesting that the majority of infected trophoblasts in the presence of DENV antibodies are likely cytotrophoblasts. These data suggest that DENV antibodies may facilitate infection of human trophoblasts, consistent with our data in mice.
Enhancement of ZIKV Pathogenesis by Dengue VirusReactive Antibodies Is FcgR Mediated In Vivo
Our in vivo studies clearly demonstrate that DENV-specific IgG mediates enhancement of ZIKV pathogenicity, and data using FcgR blocking antibodies in human placental explants further point to a role for FcgRs in mediating this effect. To address this, we obtained a previously described human monoclonal antibody clone, ZKA78, which is cross-reactive to and can enhance both DENV and ZIKV in vitro (Stettler et al., 2016) , as well as its LALA (leucine [L] to alanine [A] substitution at position 234 and 235) counterpart, which is incapable of engaging FcgRs. We injected 1 mg/mouse (0.05 mg/kg) of ZKA78 or ZKA78 LALA into pregnant Stat2 À/À mice at E6.5 2 h prior to infection with ZIKV, as we have previously done in Figure 1 .
As shown in Figure 7A , mice that received the ZKA78 antibody prior to ZIKV infection showed increased maternal weight loss post infection compared to mice receiving the ZKA78 LALA antibody (p = 0.027). This was also accompanied by a significant increase in fetal resorption rates, with pregnant dams that received ZKA78 having a resorption rate of 50% compared to 18.2% observed in mice that received the ZKA78 LALA (p = 0.034; Figure 7B ). Fetuses harvested at E13.5 from ZIKV-infected pregnant dams receiving ZKA78 were significantly smaller than those harvested from mice that had received ZKA78 LALA (p < 0.0001; Figures 7C and 7D ). Overall, these data provide compelling evidence that cross-reactive antibodies are capable of enhancing ZIKV-mediated fetal damage in an FcgR-dependent fashion. Immune plasma or IgG were also added to the media at the same concentration every other day during the media change. Each condition was tested using triplicate wells (27 blocks of tissue per condition in total) along with an uninfected donor-matched condition. The total amount of virus produced was measured by plaque assay on days 2 (A and D), 4 (B and E), and 6 (C and F) post infection.
(G-J) Placental tissues were incubated with blocking antibodies against FcRn (G), CD64 (FcgRI; H), CD32 (FcgRII; I), or CD16 (FcgRIII; J) at a concentration of 1 mg/mL for 24 h prior to infection with ZIKV that was pre-incubated with DENV-immune plasma; blocking antibodies were maintained in culture media and the total virus production over all 6 days is shown. Dotted line indicates the limit of detection. Significance was determined using the Wilcoxon matched pairs signedrank test. *p < 0.05, ***p < 0.001. See also Figure S4 .
DISCUSSION
This study reports evidence linking prior DENV infection with the severe disease phenotype caused by ZIKV during pregnancy. In both the mouse and human infection models, the hallmark of enhanced ZIKV infection caused by DENV antibodies was the increase in infected trophoblasts. Trophoblasts are critical for normal placental function and fetal development-dysfunction of these cells has been shown to lead to intrauterine growth restriction, impaired neurological development, and miscarriage (Gil-Sá nchez et al., 2011; Tabata et al., 2015; Woods et al., 2017; Yougbaré et al., 2017) , much like the pathology observed in ZIKV infection in humans during pregnancy. In fact, trophoblasts become less susceptible to ZIKV infection during mid to late gestation (Bayer et al., 2016; Corry et al., 2017; Sheridan et al., 2017; Tabata et al., 2016) because they have been shown to constitutively express IFNl, which is consistent with the increased resistance to ZIKV infection observed in mice infected later in gestation. This is also supported by human epidemiologic data showing fewer birth defects in women infected with ZIKV later in gestation ( Tissue sections were co-stained for ZIKV RNA using in situ hybridization (red) and either MAC-2 for macrophages (A and B) or CK19 for trophoblasts (C and D) shown in green. DAPI was used to identify nuclei (blue). Scale bars indicate 100 mm. Cells double positive for ZIKV and either MAC-2 (B) or CK19 (D) were quantified across the three donors that were co-stained for ZIKV RNA using in situ hybridization (blue circles) combined with four donors that were co-stained for ZIKV NS3 using immunofluorescence (red squares of and/or access to early-gestation placental trophoblasts in the presence of DENV-specific antibodies may explain the high rates of ZIKV-induced birth defects and spontaneous abortions that have occurred in DENV-endemic regions (Brasil et al., 2016) . Infected trophoblasts may exacerbate damage to the developing fetus indirectly by restricting transfer of oxygen and nutrients to the fetus. Our data also show that DENV antibodies increase the breakdown of placental architecture during ZIKV infection, which may also directly impact fetal development. Although we did not observe a significant difference in the proportion of infected macrophages relative to all infected cells between mice that received CTRL antibodies and mice that received DENV antibodies, we did see an increase in the total number of infected macrophages in the DENV antibody condition, which may contribute to the overall heightened viral load in the placenta. This is consistent with a recently published study showing that DENV antibodies can increase infection of full-term placental macrophages (Zimmerman et al., 2018) . However, our data suggest that the majority of the increase in viral load is due to increased infection of trophoblasts.
Our data suggest that the worsened fetal outcome during ZIKV infection in the presence of DENV antibodies is FcgR mediated. It is well established that FcRn expression increases as gestational age increases and that FcRn is responsible for the transplacental transfer of IgG (Lozano et al., 2018; van den Berg et al., 2011) . However, ablation of the ability for antibody to bind to FcgRs decreased ZIKV replication in human tissue and pathogenesis in mice. This suggests that despite the low expression levels of FcRn during early gestation, the binding of DENV antibodies to FcgRs is still sufficient to exacerbate pathogenesis during pregnancy. We can envision several possible mechanisms for ADE of ZIKV in the placenta: (1) syncytiotrophoblasts are first infected in an FcgR-dependent fashion, allowing the virus to disseminate into the placenta; (2) peripheral enhancement of ZIKV infection combined with inflammation may promote tissue damage and weaken the placental barrier; and (3) low levels of FcRn expression during early gestation are sufficient for the delivery of enhancing concentrations of DENV antibodies into the placenta (Simister, 1998) . In order to determine the precise role of individual Fc receptors during ADE of ZIKV in the context of pregnancy, tissue-specific knockout mice will likely be important tools to investigate this further.
It is important to note that our study only evaluates the role of antibodies in mediating ADE of ZIKV. Recent studies have also shown that anti-DENV CD8 + T cells can offer protection against subsequent ZIKV infections in mice (Wen et al., 2017) . Although natural immunity to DENV involves both antibody and T cell responses, in the context of pregnancy, a passive transfer model like the one used here, which solely evaluates the role of antibodies, may be more relevant because antibodies, but not T cells, can be transferred across the placenta. The interplay between the humoral and cellular immune responses against DENV, the timing of the ZIKV infection after an initial DENV infection, and the immune state at the time of infection (particularly during pregnancy) are all likely to impact the extent of ADE of ZIKV that may occur in humans. Currently, it is not clear whether prior exposure to DENV, either through infection or vaccination, impacts clinical syndromes during ZIKV infection in humans, nor is there a clear time frame between sequential infections identified to observe such an effect. These questions are very challenging to address because of the high level of cross-reactivity among flaviviruses, which makes it difficult to serologically differentiate ZIKV and DENV infection. One human study with a relatively small patient population (Terzian et al., 2017) and two macaque studies (McCracken et al., 2017; Pantoja et al., 2017) evaluating how DENV immunity impacts ZIKV pathogenesis showed no increase in viremia. However, identification of enhancement of ZIKV infection caused by preexisting DENV immunity is complex and may be highly dependent on numerous factors, such as the timing of sequential infections, circulating antibody levels, cell-mediated responses, or disease parameter definitions. Furthermore, ADE only occurs at subneutralizing concentrations of cross-reactive antibodies (Katzelnick et al., 2017; Kliks et al., 1988) ; high levels of DENV-specific antibodies are protective against ZIKV at high concentrations (Bardina et al., 2017; Fernandez et al., 2017; Robbiani et al., 2017) . Epidemiologic studies that evaluate the extent to which congenital ZIKV disease is impacted by prior infection with DENV should consider circulating DENV antibody levels at the time of infection because DENV immunity can be both protective and enhancing. This is exemplified by a recent study evaluating the incidence of ADE after sequential DENV infections, which showed that waning DENV antibodies can enhance subsequent infection with a heterotypic DENV serotype within a distinct window of antibody levels (Katzelnick et al., 2017) . Thus, human epidemiologic studies that do not characterize DENV antibody titers at the time of ZIKV infection will likely see no differences (Halai et al., 2017) .
It is possible that ADE of ZIKV may only be apparent in humans and non-human primates under specific immunologic circumstances, such as pregnancy. This is highlighted by the fact that the recent ZIKV outbreaks only gained prominence as the virus's association with microcephaly and other birth defects became apparent. Numerous non-human primate studies have now shown that ZIKV can cause placental pathology, with detectable virus in the placental chorionic villi (Adams Waldorf et al., 2016; Dudley et al., 2018; Hirsch et al., 2018; Martinot et al., 2018; Nguyen et al., 2017; Seferovic et al., 2018) . Further, primary placental macrophages have been shown to be significantly more susceptible to ZIKV in the presence of DENV antibodies (Zimmerman et al., 2018) . Thus, studies evaluating ADE of ZIKV in the context of pregnancy should be conducted in primates and examined epidemiologically in humans.
Understanding the interplay between sequential DENV-ZIKV infections in humans will have profound implications for the development of flavivirus vaccines and antibody therapeutics and could help identify at-risk populations for future outbreaks. Our data highlight the potential for antibody responses generated through DENV infection or vaccination to increase the risk of ZIKV-related diseases. Although it may take years or decades to conclusively evaluate whether ADE of ZIKV occurs in human populations, the Dengvaxia vaccine trial tells a cautionary tale for flavivirus vaccine development (Halstead, 2017) . As such, all flavivirus vaccines should consider the potential risk for ADE. Additionally, our study opens up novel opportunities for specific interventions to protect pregnant women after exposure to ZIKV, particularly in DENV endemic regions.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jean Lim (jean.lim@mssm.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS Animal Models
Mouse studies were carried out in an animal biosafety level 2 plus facility under a protocol approved by the Icahn School of Medicine at Mount Sinai Animal Care and Use Committee. Breeding pairs were formed using Stat2 À/À mice (provided by Christian Schindler; 8-10 week old nulliparous females and >8 week old non-virgin males). Females were then separated after plugs were detected (defined as E0.5) and infected at E6.5 or E10.5 as indicated.
Human Models
IgG-positive plasma from DENV-infected (n =141) blood donors was identified through screening of blood donations in the United States Territories as follows: 270,049 blood donations isolated between March 2010-August 2013 were initially screened using a DENV NS1 antigen ELISA or individual donation transcription-mediated amplification (TMA) testing (Gen-Probe, San Diego, CA). All positive hits by ELISA were further validated by TMA (both nucleic acid testing and PCR). IgM and IgG antibody testing (performed by the CDC-Dengue Branch in San Juan PR), along with DENV serotype specific assay was also performed. 141 samples tested positive for DENV-specific IgG and were thus used. Random blood donor plasma samples (n =54) that were negative for all infectious pathogens were used as negative controls. All plasma samples were individually tested for reactivity to ZIKV E protein by ELISA with recombinant ZIKV envelope protein (Protein Sciences Corp., Meriden, CT) as previously described (Bardina et al., 2017) . Immune plasma used for experiments consisted of pooled plasma samples from individuals with the highest reactivity to ZIKV E protein from 15 DENV-seropositive donors. All control plasma failed to react to ZIKV E protein, and 15 donors were pooled and used for the CTRL immune plasma condition. For placental studies, first and second trimester human placental tissue, ranging from 8 to 22 weeks of gestation (n = 17), was obtained from donors undergoing elective termination under an IRB-approved protocol (HS: 12-00145). Tissue samples from 7 week terminations were excluded from the study as no ZIKV replication was observed. Placentas were processed and cultured as expounded upon in the Method Detail section.
Cell Lines
Vero (ATCCÒ CCL81Ô) cells were used at low passage for all virus quantification by plaque assay. These cells, originally derived from kidney epithelium of a female green monkey, were obtained from the ATCC for the purposes of this study. K562 (ATCCÒ CCL-243Ô) cells, a human female lymphoblast line derived from a patient with Chronic Myelogenous Leukemia (CML) were used at low passage for all in vitro ADE experiments. K562 cells were grown at 37 C, and 5% CO 2 in RPMI supplemented with 10% FBS, 10U/ml penicillin and 10mg/ml streptomycin and 2mM L-Glutamine.
METHOD DETAILS ZIKV Infection of Stat2
-/-Mice Pregnant Stat2 À/À mice were injected intraperitoneally with 20 ml of CTRL or DENV immune plasma two hours prior to intradermal infection with 5x10 3 PFU ZIKV (strain PRVABC59, GenBank: KU501215.1) at E6.5 or E10.5. ZIKV was obtained originally from the ATCC, passaged once in Vero cells, and sequence verified. Mice were monitored daily for weight loss and symptom development, following the clinical score system used in our previous study (Bardina et al., 2017) . Fetal and maternal tissues were harvested at either E13.5 or E16.5 for analysis. Plasma samples from DENV-seropositive individuals that showed high reactivity for ZIKV E protein were pooled from 15 donors, heat inactivated, and 0.22 mm filtered. CTRL plasma samples where no reactivity to ZIKV E was detected were also pooled from 15 donors. For infections using purified IgG, pregnant Stat2 À/À mice were injected intraperitoneally with 2 ml of CTRL or DENV IgG antibodies reconstituted into PBS to the original plasma volume used for purification. Dose down experiments were conducted for in vivo experiments, and 2 ml of purified IgG was identified as the optimal amount. For infections using ZKA78 or ZKA78 LALA, 1mg/mouse (0.05mg/kg) of antibody in a volume of 200ml in PBS was injected intraperitoneally, and mice were subsequently infected as above.
ZIKV Quantification
Total RNA was isolated from tissue homogenates using Direct-zol RNA MiniPrep Plus (Zymo Research) or plasma using QIAamp viral RNA kit (Qiagen) according to the manufacturer's protocol. The following ZIKV-specific primers (5 0 -TTGGTCATGATACTGCTG ATTGC-3 0 and 5 0 -CCYTCCACRAAGTCYCTATTGC-3 0 ) and probe (5 0 -6FAM-CGGCATACAGYATCAGGTGCATWGGAG-MGBN FQ-3 0 ) were used for qRT-PCR (Schwarz et al., 2016) using the Lightcycler 480 RNA Master Hydrolysis Probes kit (Roche). For plasma, 5ml of vRNA was used for ZIKV RNA quantification; for maternal organs 100ng total RNA was used as input for ZIKV RNA quantification. For fetal heads and placentas, 1mg RNA was first reverse transcribed using High Capacity cDNA Reverse Transcription Kits (Applied Biosciences), followed by PCR using SYBR green (Roche) using the ZIKV-specific primers described above. RNA quantification was determined by fitting to an in vitro transcribed RNA standard. PCR amplification was conducted in 384-well format using the Roche LightCycler 480 System. ZIKV plaque forming units (PFU) were quantified on Vero cell monolayers whereby 250 ml of tissue culture supernatant was adsorbed for 1 hour at 37 C in 12 well plates, and cells were overlaid with 1 ml DMEM (Invitrogen) supplemented with 0.8% methyl cellulose, 2% FBS, and 50 mg/ml gentamicin sulfate. Cells were incubated for 5 days at 37 C, fixed with 4% PFA, and stained with crystal violet for plaque visualization.
ZIKV RNA Detection by In Situ Hybridization and Immunofluorescence Co-staining Tissues were fixed in 10% neutral buffered formalin for 24 hours and placed back into PBS until paraffin embedding. In situ hybridization using RNAscopeÒ was performed on 5 mm paraffin-embedded sections. Deparaffinization was performed by baking slides at 55 C for twenty minutes. Following this step, slides were washed twice with xylene for five minutes each, twice in 100% ethanol for two minutes each, and lastly slides were dried for five minutes at 60 C. Slides were then incubated with hydrogen peroxide for 10 minutes at RT, and were subsequently washed in diH 2 O. Target retrieval was performed by incubating slides in Target Retrieval solution at 100 C for 15 minutes. Lastly, slides were washed with water and transferred into 100% ethanol for three minutes, then were allowed to dry. Sections were treated with RNAscopeÒ Protease Plus and incubated at 40 C for 30 minutes. Slides were then washed with diH 2 O. Fluorescence in situ hybridization was subsequently performed according to the manufacturer's protocol (ACD# 323110) with RNAscopeÒ Probe V-ZIKVsph2015 (ACD #467871; binds sense RNA) as previously described . Following in situ hybridization, slides were washed twice for five minutes in Tris-buffered Solution containing 0.01% Tween-20 (TBST) and subsequently blocked in a solution of 2.5% goat serum and 2.5% BSA in TBST for 30 minutes at RT. For co-stains, sections were incubated for 1 hour at 4 C with monoclonal rat anti-MAC2 antibody (1:500, clone M3/38, Cedarlane) or rabbit monoclonal anti-cytokeratin 19 (1:100, clone EP1580Y, Abcam), or overnight at 4 C with rabbit polyclonal anti-syncytin (1:50, ab71115, Abcam) and then mounted with Vectashield hard-set mounting medium with DAPI (Vector Laboratories). Slides were analyzed using an AxioImager Z2 microscope (Zeiss) and Zen 2012 software (Zeiss). Cell quantifications were conducted using CellProfiler Analyst software. For mouse placentas, cells were quantified across the entire placental slice, with 4,000 cells counted on average per slice. The percentage of ZIKV+ macrophages or trophoblasts was calculated for each placenta, and the percentages were averaged. For the CTRL condition, 5 individual placentas were quantified; for DENV condition, 9 individual placentas were quantified. For the quantification of human placentas, three placental donors were evaluated by RNA ISH, and four placental donors were evaluate using NS3 staining (described below). Because nearly identical quantifications were found using both methods, these quantifications were combined as human placental tissues were limited. On average, 3,000 cells were counted per donor per condition, with image analysis spanning the entire tissue slice. Significance was calculated using the Mann-Whitney test for mouse placentas and Wilcoxon matched pairs signed-rank test for human placentas.
H&E and Vimentin Staining
Tissues were fixed in 10% neutral buffered formalin before embedding into paraffin and cutting 5mm sections. Deparaffinization and antigen retrieval was performed as previously described (Bardina et al., 2017) . Slides were stained with hematoxylin (Gill's formula, Vector Laboratories H3401) and eosin Y (Sigma Aldrich E4009) according to manufacturer's instructions. For vimentin staining, slides were blocked in TBST containing 2.5% normal goat serum for 40 minutes at RT, washed and incubated with rabbit monoclonal antivimentin antibody (1:1000, clone EPR3776, Abcam) for 1 hour at 4 C, then washed and incubated with goat anti-rabbit Alexa Fluor 488 before mounting with Vectashield as described above and imaging with an AxioImager Z2 microscope (Zeiss) and Zen 2012 software.
Cytokine and Chemokine Protein Quantification
Placental tissue homogenates were evaluated for 21 cytokines/chemokines by multiplex ELISA for the following analytes: CCL2/ MCP-1, CCL3/MIP-1a, CCL4/MIP-1b, CCL5/RANTES, CCL7/MCP-3, CCL20/MIP-3a, CXCLl1/GROa, CXCL2/GROb, CXCL9/ MIG, CXCL10/IP-10, GM-CSF, IFNg, IL1b, IL-4, IL-6, IL-10, IL-15, IL-17A, IL-22, IL-2, and TNFa as previously described (Aguado et al., 2015) . Samples were analyzed on a Luminex MAGPIX platform. For each sample, >50 beads were collected per analyte. The median fluorescence intensity of these beads was recorded and used for analysis with the Milliplex Analyst software using a 5P regression algorithm. Heat maps for fold induction were generated in R by logarithmic transformation of the mean cytokine level in the ZIKV-infected conditions divided by the mean cytokine level of uninfected controls, normalized per gram of tissue. Hierarchical clustering was performed using the hclust function in R, which stratifies Euclidian distance.
Ex Vivo Infection of Human Placental Tissue
First and second trimester human placental tissue was obtained within two hours of surgery from donors undergoing elective termination under an IRB-approved protocol (HS: 12-00145). Chorionic villi adjacent to the fetal chorionic plate were placed into prewarmed DMEM containing 25% F-12 media, 10% FBS, 5 mM HEPES, 2 mM Glutamine, 100 IU/ml Penicillin, 100 mg/ml Streptomycin, 2.5 mg/ml Fungizone, and 300 ng/ml Timentin as previously described (Weisblum et al., 2017) . After removal of the amnion and decidua, the chorionic villi were cut into 0.2 cm 3 blocks; nine blocks were plated per well of a six-well plate onto collagen gelfoams (Cardinal Health) in 3 ml media, and 3 wells were used per condition (27 tissue blocks). Following an overnight incubation at 37 C, tissue blocks were individually infected with 1x10 4 PFU ZIKV PRVABC59 per tissue block in a volume of 5 ml that was pre-incubated with CTRL or DENV immune plasma or IgG (diluted 1:250) for 1 hour. Supernatants were collected and media changed every other day; immune plasma or IgG was replenished in the culture media at a dilution of 1:250 upon media change. For inhibition experiments, anti-FcRn (Genetex, clone 1G3), anti-CD16 (eBioscience, clone eBioCB16), anti-CD32 (eBioscience, clone 6C4), or anti-CD64 (eBioscience, clone 10.1) antibodies were added into the culture media at a concentration of 1mg/mL for 24 hours prior to infection. FcR inhibitors were maintained in culture media throughout the experiment.
Purification of IgG from Human Plasma
Heat-inactivated pooled human plasma samples were diluted approximately 1:10 in PBS and filtered through a 0.22m filter unit. The diluted plasma was then run through a sepharose-G (GE Healthcare) column three times and the flow through was collected. The column was washed with three column volumes PBS (approximately 150 ml) and IgG was eluted with 45 ml of 0.1M glycine-HCl buffer (pH 2.7) into 5 ml of 2M Tris-HCl buffer (pH 10). The resulting 50 ml of IgG solution were then concentrated using Amicon Ultra centrifugation units (30 kDa cutoff, Millipore) and washed three times with 15 ml of PBS. Finally, the purified IgG was taken up in a volume of PBS corresponding to the original plasma volume used for purification.
ZIKV E Protein ELISAs ZIKV E protein ELISA was performed as described previously (Bardina et al, 2017) . Briefly, recombinant ZIKV E protein (Protein Sciences Corp., Meriden, CT) was coated on Immulon plates overnight at 4 C at a concentration of 2 mg/ml in coating buffer (0.1 M Na2CO3-NaHCO3, pH 9.4). Plates were then blocked for 1 hour at RT in 3% dry milk powder in PBS containing 0.1% Tween 20 (PBS-T). Meanwhile, heat-inactivated plasma or purified IgG was diluted 1:3 starting with a 1:100 dilution in blocking buffer in a separate plate. Positive controls (4G2, murine hybridoma-derived anti-flavivirus E) and negative controls (murine isotype control antibodies) were used on each plate to evaluate standardization. All control monoclonal antibodies were diluted 1:3 with a 10 mg/mL initial concentration in blocking buffer. Blocking buffer was then removed and purified IgG or immune plasma added. After a two-hour incubation phase, plates were washed four times with PBS-T and a secondary stain containing horseradish peroxidase conjugated anti-human IgG antibody (Sigma A0293, 1:3,000) was diluted in blocking buffer and added. After a one-hour incubation in secondary antibody, plates were washed four times with PBS-T and developed with SigmaFast o-phenylenediamine dihydrochloride (OPD) (Sigma, 100 ml per well). After 10 minutes of development, the reaction was stopped with 3 M HCl. The optical density (OD) at 490 nm was read on a plate reader and background levels were analyzed in Microsoft Excel, and net optical density over background graphed in GraphPad PRISM with four-parameter logarithmic regressions.
In Vitro Antibody-Dependent Enhancement of ZIKV Infection Antibody-dependent enhancement of ZIKV infection was measured using a flowcytometry-based assay. Briefly, different dilutions of plasma or purified IgG were mixed with ZIKV PRVABC59 (MOI of 1) for 1 hour at 37 C and then added to K562 cells (5 x 10 4 ) in 96 well U bottom plates in RPMI 1640 media supplemented with 10% FBS, 2mM L-glutamine, and 10U/ml penicillin and 10mg/ml streptomycin. After 2 days, cells were fixed with 4% PFA, permeabilized with PBS containing 0.2% BSA and 0.05% saponin, and stained with 4G2 antibody (1 mg/ml) for 1 hour at room temperature. After washing, cells were incubated with goat anti-mouse IgG conjugated to phycoerythrin (1mg/ml, Invitrogen) for 1 hr at room temperature. The number of infected cells was determined by flow cytometry using a FACS Caliber and analyzed using FlowJo2 software version 10.1.r7.
HCGb and hPL ELISA Supernatants from uninfected placental tissues were collected on day 2, day 4, and day 6 post culture. HCGb (human beta chorionic gonadotropin) and human placental lactogen (hPL) levels were determined using R&D Systems DuoSetÒ ELISA Development System and AlpcoÒ HPL ELISA kits, respectively. Procedures were followed per manufacturer's instructions. The kit-provided standards and samples were measured with each assay in duplicate. For both kits, supernatants from human tonsil explants cultured ex vivo were used as a negative control.
